OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a leading Contract Research Organization (CRO) specializing in gene therapy based in China, has entered into a partnership with Shenzhen Innovation Immunotechnology Co., Ltd. As per the agreement, OBiO will offer preclinical pharmaceutical research services for Shenzhen Innovation’s TCR-T cell therapy candidate, SIIT-T002. This collaboration aims to facilitate a seamless Investigational New Drug (IND) filing process for the pipeline candidates. Additionally, OBiO will provide IND filing CMC (Chemistry, Manufacturing, and Controls) services to support the development of a range of TCR-T cell-related products, encompassing the production of retroviral vectors and TCR-T cell samples.
As a Contract Development and Manufacturing Organization (CDMO) focused on gene and cell therapies, OBiO boasts an impressive infrastructure, including 15 carrier production lines, 20 cell production lines, and an integrated freeze-dried and filled formulation filling line specifically designated for gene and cell therapy products.- Flcube.com
